A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 606-613

  Sánchez Lázaro, Ignacio J ^a   Almenar, Luis ^a   Martínez Dolz, Luis ^a   Buendía Fuentes, Francisco ^a   Agüero, Jaime ^a   Navarro Manchón, Josep ^a   Vicente, José Luis ^a   Salvador, Antoinio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Cyclosporine; Heart transplantation; Immunosuppression; Renal function; Tacrolimus

Indexed keywords

ATORVASTATIN; CYCLOSPORIN A; DACLIZUMAB; DEFLAZACORT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREGNENEDIONES; PROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 80051686909     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01309.x     Document Type: Article

References (29)

1. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967: 41: 1271.
2. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Eight year results of cyclosporine-treated patients with cardiac transplants. J Thorac Cardiovasc Surg 1990: 99: 500.
3. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report-2001. J Heart Lung Transplant 2001: 20: 805.
4. Fritsche L, Dragun D, Neumayer HH, Budde K. Impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc 2004: 36(2 Suppl): 130S.
5. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989: 2: 1000.
6. Verleden GM, Dupont LJ, Van Raemdonck D, Vanhaecke J. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 2003: 22: 908.
7. Pham SM, Kormos RL, Hattler BG et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996: 111: 764.
8. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999: 18: 336.
9. Rinaldi M, Pellegrini C, Martinelli L et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997: 16: 1001.
10. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009: 28: 1007.
11. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004: 78: 591.
12. Wang CH, Ko WJ, Chou NK, Wang SS. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. Transplant Proc 2004: 36: 2384.
13. Pollock-Barziv SM, Dipchand AI, McCrindle BW, Nalli N, West LJ. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 2005: 24: 190.
14. Grimm M, Rinaldi M, Yonan NA et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006: 6: 1387.
15. Kobashigawa JA, Patel J, Furukawa H et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006: 25: 434.
16. Groetzner J, Meiser BM, Schirmer J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc 2001: 33: 1461.
17. Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002: 74: 1568.
18. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006: 6: 1377.
19. Caravaca F, Arrobas M, Luna E, Naranjo M, Pizarro JL, Sánchez-Casado E. The glomerular filtration rate estimated by MDRD predictive equation in unselected end-stage renal failure patients: differences from average of creatinine and urea clearances. Nefrología 2002: 22: 432.
20. Sánchez Lázaro IJ, Almenar Bonet L, Martínez-Dolz L et al. Effect of clinical trials on survival after heart transplantation. Transplant Proc 2008: 40: 3044.
21. Hesselink D, Van Gelder T. The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. Transplant Rev 2003: 17: 158.
22. Almenar Bonet L. Spanish heart transplantation registry. 19th Official Report of the Spanish Society of Cardiology Working Group on Heart Failure, Heart Transplantation and Associated Therapies (1984-2007). Rev Esp Cardiol 2008: 61: 1178.
23. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005: 24: 1710.
24. Kanter J, Pallardó L, Gavela E et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant Proc 2009: 41: 2156.
25. Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009: 28: 58.
26. Sánchez-Lázaro IJ, Martínez-Dolz L, Almenar-Bonet L, Moro-López JA, Agüero J et al. Predictor factors for the development of arterial hypertension following heart transplantation. Clin Transplant 2008: 22: 760.
27. Kass M, Haddad H. Cardiac allograft vasculopathy: pathology, prevention and treatment. Curr Opin Cardiol 2006: 21: 132.
28. Martínez-Dolz L, Almenar L, Martínez-Ortiz L et al. Predictive factors for development of diabetes mellitus post-heart transplant. Transplant Proc 2005: 37: 4064.
29. Arora S, Aukrust P, Andreassen A et al. The prognostic importance of modifiable risk factors after heart transplantation. Am Heart J 2009: 158: 431.